Generation Bio has announced new data showing that its investigational non-viral gene therapy platform can increase levels of the clotting protein factor VIII (FVIII) in mouse and non-human primate models of hemophilia A. The data support the selection of a final candidate therapy for clinical development later this year, the company said in a press release. Hemophilia A is caused by missing or defective FVIII due to mutations in the gene that provides instructions to…

You must be logged in to read/download the full post.